UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 1)1

ESSA Pharma Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

29668H708

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed

Rule 13d-1(b)

X Rule 13d-1(c)

Rule 13d-1(d)

1.The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 29668H708

1.NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

Pfizer Inc. 13-5315170

2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3.SEC USE ONLY

4.CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.SOLE VOTING POWER 1,675,000

6.SHARED VOTING POWER -0-

7.SOLE DISPOSITIVE POWER 1,675,000

8.SHARED DISPOSITIVE POWER -0-

9.AGGREGATE AMOUNT BENEFICIALLY OWNED

BY EACH REPORTING PERSON

1,675,000*

10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.81% *

12.TYPE OF REPORTING PERSON CO

* Based on 44,015,870 shares of Common Stock outstanding as set forth in the Issuer s Quarterly Report on Form 10-Q for the quarter ended on December 31, 2021, filed with the SEC on February 3, 2022.

Page 2 of 5

CUSIP No. 29668H708

SCHEDULE 13G

ITEM 1(a)

NAME OF ISSUER

ESSA Pharma Inc.

ITEM 1(b)

ADDRESS OF ISSUER S PRINCIPAL EXECUTIVE OFFICES

Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5

ITEM 2(a)

NAME OF PERSON FILING

Pfizer Inc.

ITEM 2(b)

ADDRESS OF PRINCIPAL BUSINESS OFFICE

235 East 42nd Street, New York, NY 10017

ITEM 2(c)

CITIZENSHIP

Delaware

ITEM 2(d)

TITLE OF CLASS OF SECURITIES

Common Shares, no par value

ITEM 2(e)

CUSIP NUMBER

29668H708

ITEM 3

STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C)

Not applicable.

Page 3 of 5

CUSIP No. 29668H708

ITEM 4

OWNERSHIP

The information requested in this item is incorporated herein by reference to the cover page to this Schedule 13G.

ITEM 5

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

ITEM 6

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable.

ITEM 7

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY

Not applicable.

ITEM 8

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable.

ITEM 9

NOTICE OF DISSOLUTION OF GROUP

Not applicable.

ITEM 10

CERTIFICATION

By signing below the undersigned certifies that, to the best of the undersigned s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

Page 4 of 5

CUSIP No. 29668H708

SIGNATURE

After reasonable inquiry and to the best of the undersigned s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated February 11, 2022

PFIZER INC.

By

s Susan Grant

Name

Susan Grant

Title

Assistant Secretary

Page 5 of 5